Loading...

We've got a brand new version of Simply Wall St! Try it out

MYOS RENS Technology

Nasdaq:MYOS
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MYOS
Nasdaq
$13M
Market Cap
  1. Home
  2. US
  3. Household
Company description

MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional and therapeutic products that enhance muscle health and performance. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
MYOS Share Price and Events
7 Day Returns
-13.7%
NasdaqCM:MYOS
2.2%
US Personal Products
0.3%
US Market
1 Year Returns
17%
NasdaqCM:MYOS
20.5%
US Personal Products
12.5%
US Market
MYOS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MYOS RENS Technology (MYOS) -13.7% -3.7% -9.7% 17% -15.3% -85.1%
US Personal Products 2.2% -1.1% 5.5% 20.5% 54.3% 59.2%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • MYOS underperformed the Personal Products industry which returned 20.5% over the past year.
  • MYOS outperformed the Market in United States of America which returned 12.5% over the past year.
Price Volatility
MYOS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is MYOS RENS Technology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MYOS RENS Technology. This is due to cash flow or dividend data being unavailable. The share price is $1.3801.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MYOS RENS Technology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MYOS RENS Technology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:MYOS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.38
NasdaqCM:MYOS Share Price ** NasdaqCM (2019-11-12) in USD $1.38
United States of America Personal Products Industry PE Ratio Median Figure of 21 Publicly-Listed Personal Products Companies 17.08x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MYOS RENS Technology.

NasdaqCM:MYOS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MYOS Share Price ÷ EPS (both in USD)

= 1.38 ÷ -0.38

-3.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYOS RENS Technology is loss making, we can't compare its value to the US Personal Products industry average.
  • MYOS RENS Technology is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does MYOS RENS Technology's expected growth come at a high price?
Raw Data
NasdaqCM:MYOS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
United States of America Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.56x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MYOS RENS Technology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MYOS RENS Technology's assets?
Raw Data
NasdaqCM:MYOS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.26
NasdaqCM:MYOS Share Price * NasdaqCM (2019-11-12) in USD $1.38
United States of America Personal Products Industry PB Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.65x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqCM:MYOS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MYOS Share Price ÷ Book Value per Share (both in USD)

= 1.38 ÷ 0.26

5.36x

* Primary Listing of MYOS RENS Technology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MYOS RENS Technology is overvalued based on assets compared to the US Personal Products industry average.
X
Value checks
We assess MYOS RENS Technology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. MYOS RENS Technology has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MYOS RENS Technology expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
81.6%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is MYOS RENS Technology expected to grow at an attractive rate?
  • Unable to compare MYOS RENS Technology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MYOS RENS Technology's earnings growth to the United States of America market average as no estimate data is available.
  • MYOS RENS Technology's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:MYOS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:MYOS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 81.6%
United States of America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:MYOS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:MYOS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 5 2
2020-12-31 2 2
2019-12-31 1 2
2019-11-13
NasdaqCM:MYOS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -3 -3
2019-06-30 1 -3 -3
2019-03-31 0 -2 -3
2018-12-31 0 -3 -3
2018-09-30 0 -3 -4
2018-06-30 0 -3 -4
2018-03-31 0 -3 -4
2017-12-31 1 -4 -4
2017-09-30 0 -4 -4
2017-06-30 0 -4 -4
2017-03-31 0 -4 -4
2016-12-31 0 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MYOS RENS Technology is high growth as no earnings estimate data is available.
  • MYOS RENS Technology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:MYOS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from MYOS RENS Technology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:MYOS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-11-13
NasdaqCM:MYOS Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.38
2019-06-30 -0.38
2019-03-31 -0.40
2018-12-31 -0.45
2018-09-30 -0.62
2018-06-30 -0.63
2018-03-31 -0.68
2017-12-31 -0.69
2017-09-30 -0.67
2017-06-30 -0.75
2017-03-31 -0.81
2016-12-31 -0.90

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MYOS RENS Technology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MYOS RENS Technology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MYOS RENS Technology has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MYOS RENS Technology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MYOS RENS Technology's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MYOS RENS Technology does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare MYOS RENS Technology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MYOS RENS Technology's 1-year growth to the US Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
MYOS RENS Technology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MYOS RENS Technology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:MYOS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.80 -3.14 4.60
2019-06-30 0.52 -3.13 4.43
2019-03-31 0.45 -2.99 4.25
2018-12-31 0.36 -3.22 4.44
2018-09-30 0.37 -4.24 4.39
2018-06-30 0.46 -4.08 4.32
2018-03-31 0.43 -4.15 4.39
2017-12-31 0.53 -4.06 4.29
2017-09-30 0.40 -3.73 4.08 -0.02
2017-06-30 0.28 -3.84 4.03 -0.01
2017-03-31 0.28 -4.24 4.36
2016-12-31 0.33 -4.34 4.32
2016-09-30 0.34 -4.89 4.91 -0.62
2016-06-30 0.33 -5.32 4.75 -0.40
2016-03-31 0.35 -4.99 4.04 -0.19
2015-12-31 0.16 -5.30 4.23
2015-09-30 0.14 -4.87 3.84 0.89
2015-06-30 0.21 -5.75 4.83 1.02
2015-03-31 1.80 -5.57 5.78 1.10
2014-12-31 3.34 -4.46 5.62 1.35
2014-09-30 4.74 -5.01 6.26 1.45
2014-06-30 5.55 -3.61 5.79 1.20
2014-03-31 4.59 -3.59 5.38 1.01
2013-12-31 3.32 -4.26 5.31 0.75
2013-09-30 2.09 -3.87 4.30 0.59
2013-06-30 1.54 -3.90 4.18 0.49
2013-03-31 1.16 -4.51 3.50 0.39
2012-12-31 0.91 -3.91 2.88 0.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MYOS RENS Technology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MYOS RENS Technology has efficiently used its assets last year compared to the US Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MYOS RENS Technology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MYOS RENS Technology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MYOS RENS Technology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MYOS RENS Technology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MYOS RENS Technology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MYOS RENS Technology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MYOS RENS Technology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MYOS RENS Technology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MYOS RENS Technology Company Filings, last reported 1 month ago.

NasdaqCM:MYOS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 2.37 0.79 0.40
2019-06-30 3.25 0.79 1.16
2019-03-31 4.40 0.78 2.20
2018-12-31 2.82 1.02 0.02
2018-09-30 2.85 0.76 0.46
2018-06-30 3.73 0.01 0.51
2018-03-31 3.56 0.04 0.23
2017-12-31 4.36 0.07 0.92
2017-09-30 4.39 0.00 0.47
2017-06-30 5.10 0.00 1.14
2017-03-31 6.17 0.00 2.24
2016-12-31 5.32 0.00 1.87
2016-09-30 5.32 0.58 2.89
2016-06-30 6.15 0.58 3.75
2016-03-31 7.52 0.58 5.22
2015-12-31 3.51 0.68 0.88
2015-09-30 4.60 0.30 0.79
2015-06-30 5.73 0.50 1.30
2015-03-31 5.49 0.00 0.59
2014-12-31 6.74 0.00 1.57
2014-09-30 5.56 0.22 0.64
2014-06-30 7.24 0.00 2.30
2014-03-31 7.88 0.00 3.91
2013-12-31 3.34 0.00 0.45
2013-09-30 4.45 0.00 1.88
2013-06-30 4.93 0.00 2.60
2013-03-31 5.46 0.00 3.17
2012-12-31 6.20 0.00 3.98
  • MYOS RENS Technology's level of debt (33.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.9% vs 33.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MYOS RENS Technology has less than a year of cash runway based on current free cash flow.
  • MYOS RENS Technology has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.1% each year.
X
Financial health checks
We assess MYOS RENS Technology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MYOS RENS Technology has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MYOS RENS Technology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MYOS RENS Technology dividends.
If you bought $2,000 of MYOS RENS Technology shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MYOS RENS Technology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MYOS RENS Technology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:MYOS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:MYOS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-11-13

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MYOS RENS Technology has not reported any payouts.
  • Unable to verify if MYOS RENS Technology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MYOS RENS Technology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MYOS RENS Technology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MYOS RENS Technology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MYOS RENS Technology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MYOS RENS Technology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MYOS RENS Technology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Mannello
COMPENSATION $70,710
AGE 61
TENURE AS CEO 2.3 years
CEO Bio

Mr. Joseph Mannello, also Known as Joe, has been the Chief Executive Officer of MYOS RENS Technology Inc. since August 24, 2017 and served as its Interim Chief Executive Officer from September 1, 2016 to August 24, 2017. Mr. Mannello served as a Consultant of MYOS RENS Technology Inc. since May 2015 until September 2016. Mr. Mannello has more than 27 years of experience in fixed income and financial services. He served as the Executive Managing Director at Brean Capital, LLC since March 2013 until May 2015. Mr. Mannello served as Head of Corporate Credit and Executive Managing Director of Gleacher & Company, Inc., since March 2008 until March 2012. He served as the Head of Debt Capital Markets at Broadpoint Gleacher Securities Group, Inc. Mr. Mannello joined Gleacher & Company in 2008. He served as Executive Managing Director and Head of Corporate Credit Division at Gleacher & Company Securities, Inc. Mr. Mannello served as an Executive Managing Director and Head of Fixed Income Division of Broadpoint Securities Group, Inc. since January 2008. At BNY Capital Markets, Mr. Mannello served as the Head of Fixed Income and Managing Director from 1998 to 2008. Prior to BNY Capital Markets, he founded Mendham Capital. Mr. Mannello started his career with Printon Kane Group in 1981 and served as its Partner since 1984 and President since 1990. He has been Director of MYOS RENS Technology Inc., since December 17, 2015. Mr. Mannello graduated from Rutgers University in 1979.

CEO Compensation
  • Joe's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Joe's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the MYOS RENS Technology management team in years:

2.3
Average Tenure
60
Average Age
  • The tenure for the MYOS RENS Technology management team is about average.
Management Team

Bob Hariri

TITLE
Chairman of Board & Chairman of the Scientific Advisory Board
COMPENSATION
$16K
AGE
60

Joe Mannello

TITLE
CEO & Director
COMPENSATION
$71K
AGE
61
TENURE
2.3 yrs

Ren Ren

TITLE
Global Chairman
COMPENSATION
$15K
AGE
57
TENURE
3.7 yrs

Joseph DiPietro

TITLE
Controller
TENURE
3.2 yrs

Magshoud Dariani

TITLE
Chief Technology Officer

Kris Ohrenick

TITLE
Head of Marketing
TENURE
1.8 yrs

Dante Carnevale

TITLE
Chief Strategist
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the MYOS RENS Technology board of directors in years:

4.8
Average Tenure
58.5
Average Age
  • The tenure for the MYOS RENS Technology board of directors is about average.
Board of Directors

Bob Hariri

TITLE
Chairman of Board & Chairman of the Scientific Advisory Board
COMPENSATION
$16K
AGE
60
TENURE
7.6 yrs

Joe Mannello

TITLE
CEO & Director
COMPENSATION
$71K
AGE
61
TENURE
3.9 yrs

Ren Ren

TITLE
Global Chairman
COMPENSATION
$15K
AGE
57
TENURE
3.7 yrs

Chris Pechock

TITLE
Independent Director
COMPENSATION
$43K
AGE
54
TENURE
5.8 yrs

Victor Mandel

TITLE
Independent Director
COMPENSATION
$43K
AGE
54
TENURE
3.3 yrs

Louis Aronne

TITLE
Independent Director & Member of Scientific Advisory Board
COMPENSATION
$28K
AGE
63
TENURE
8.3 yrs

Neilank Jha

TITLE
Member of Scientific Advisory Board
TENURE
7.9 yrs

Caroline Apovian

TITLE
Member of Scientific Advisory Board
TENURE
6.8 yrs

John Nosta

TITLE
Independent Director
COMPENSATION
$33K
AGE
60
TENURE
2.9 yrs

Eric Zaltas

TITLE
Independent Director
AGE
56
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Mar 19 Buy Christopher Pechock Individual 27. Mar 19 27. Mar 19 34,247 $1.46 $50,001
27. Mar 19 Buy Joseph Mannello Individual 27. Mar 19 27. Mar 19 171,233 $1.46 $250,000
X
Management checks
We assess MYOS RENS Technology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MYOS RENS Technology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

MYOS RENS Technology Inc. (NASDAQ:MYOS) Insiders Increased Their Holdings

So shareholders might well want to know whether insiders have been buying or selling shares in MYOS RENS Technology Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' View our latest analysis for MYOS RENS Technology The Last 12 Months Of Insider Transactions At MYOS RENS Technology CEO & Director Joseph Mannello made the biggest insider purchase in the last 12 months. … NasdaqCM:MYOS Recent Insider Trading, September 3rd 2019 Insider Ownership of MYOS RENS Technology Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders.

Simply Wall St -

Easy Come, Easy Go: How MYOS RENS Technology (NASDAQ:MYOS) Shareholders Got Unlucky And Saw 88% Of Their Cash Evaporate

Some MYOS RENS Technology investors have already had a taste of the bitterness stocks like this can leave in the mouth. … Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. … MYOS RENS Technology is not the only stock insiders are buying.

Simply Wall St -

Could The MYOS RENS Technology Inc. (NASDAQ:MYOS) Ownership Structure Tell Us Something Useful?

With a market capitalization of US$16m, MYOS RENS Technology is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for MYOS RENS Technology NasdaqCM:MYOS Ownership Summary, June 27th 2019 What Does The Institutional Ownership Tell Us About MYOS RENS Technology? … As you can see, institutional investors own 5.0% of MYOS RENS Technology.

Simply Wall St -

Can We See Significant Insider Ownership On The MYOS RENS Technology Inc. (NASDAQ:MYOS) Share Register?

A look at the shareholders of MYOS RENS Technology Inc. … MYOS RENS Technology is a smaller company with a market capitalization of US$11m, so it may still be flying under the radar of many institutional investors. … We can zoom in on the different ownership groups, to learn more about MYOS

Simply Wall St -

Who Has Been Buying MYOS RENS Technology Inc. (NASDAQ:MYOS) Shares?

So we'll take a look at whether insiders have been buying or selling shares in MYOS RENS Technology Inc. … MYOS RENS Technology Insider Transactions Over The Last Year. … The insider buying may not tell us much about how insiders feel about the current share price.

Simply Wall St -

What You Must Know About MYOS RENS Technology Inc.'s (NASDAQ:MYOS) Beta Value

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

How Much Of MYOS RENS Technology Inc (NASDAQ:MYOS) Do Insiders Own?

The big shareholder groups in MYOS RENS Technology Inc (NASDAQ:MYOS) have power over the company. … With a market capitalization of US$9.0m, MYOS RENS Technology is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for MYOS RENS Technology

Simply Wall St -

Who Owns Most Of MYOS RENS Technology Inc (NASDAQ:MYOS)?

In this article, I'm going to take a look at MYOS RENS Technology Inc’s (NASDAQ:MYOS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … Check out our latest analysis for MYOS RENS Technology

Simply Wall St -

Should MYOS RENS Technology Inc's (NASDAQ:MYOS) Recent Earnings Worry You?

Today I will examine MYOS RENS Technology Inc's (NASDAQ:MYOS) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to how the rest of MYOS's industry performed. … Check out our latest analysis for MYOS RENS Technology? … MYOS is loss-making, with the most recent trailing twelve-month earnings of -US$4.15m (from 31 March 2018), which compared to last year has become

Simply Wall St -

Who Are MYOS RENS Technology Inc's (NASDAQ:MYOS) Major Shareholders?

In this article, I'm going to take a look at MYOS RENS Technology Inc’s (NASDAQ:MYOS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Private Company Ownership Potential investors in MYOS should also look at another important group of investors: private companies, with a stake of 20.07%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership level and composition in MYOS is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Company Info

Description

MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional and therapeutic products that enhance muscle health and performance. The company primarily focuses on developing products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Qurr line of products comprising flavored puddings, powders, and shakes; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform; and at the Vitamin Shoppe. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery development and commercialization of products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Details
Name: MYOS RENS Technology Inc.
MYOS
Exchange: NasdaqCM
Founded: 2007
$12,665,050
9,176,908
Website: http://www.myosrens.com
Address: MYOS RENS Technology Inc.
45 Horsehill Road,
Suite 106,
Cedar Knolls,
New Jersey, 07927,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MYOS Common Stock Nasdaq Capital Market US USD 19. Sep 2008
DB 73M Common Stock Deutsche Boerse AG DE EUR 19. Sep 2008
Number of employees
Current staff
Staff numbers
12
MYOS RENS Technology employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/13 00:13
End of day share price update: 2019/11/12 00:00
Last estimates confirmation: 2019/06/20
Last earnings filing: 2019/11/07
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.